Glomerulonephritis and Managing the Risks of Chronic Renal Disease

Pediatric Clinics of North America

Volumn 56, Issue 6, 2009, Pages 1363-1382

  Singh, Gurmeet R ^a,b,c,d  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b CHARLES DARWIN UNIVERSITY   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d JAMES COOK UNIVERSITY   (Australia)

Author keywords

Chronic kidney disease; End stage renal disease; Glomerulonephritis; Poststreptococcal glomerulonephritis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; METHYLPREDNISOLONE; PENICILLIN G; STREPTOCOCCUS VACCINE; VITAMIN;

ACUTE KIDNEY FAILURE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIALYSIS; DISEASE SEVERITY; DISEASE TRANSMISSION; DIURESIS; DRUG EFFICACY; DYSLIPIDEMIA; GLOMERULONEPHRITIS; GLYCEMIC CONTROL; GROUP B STREPTOCOCCAL INFECTION; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INDIGENOUS PEOPLE; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; NEPHRON; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PLASMAPHERESIS; PROGNOSIS; PROTEINURIA; RENAL REPLACEMENT THERAPY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING; SKIN INFECTION; SODIUM RESTRICTION;

ADOLESCENT; BLOOD GLUCOSE; CHILD; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MASS SCREENING; PROGNOSIS; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RISK REDUCTION BEHAVIOR; STREPTOCOCCAL INFECTIONS; YOUNG ADULT;

EID: 71849118427     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2009.09.014     Document Type: Review

References (141)

1. Nordstrand A., Norgren M., and Holm S.E. Pathogenic mechanism of acute post-streptococcal glomerulonephritis. Scand J Infect Dis 31 6 (1999) 523-537
2. Carapetis J.R., Steer A.C., Mulholland E.K., et al. The global burden of group A streptococcal diseases. Lancet Infect Dis 5 11 (2005) 685-694
3. Steer A.C., Danchin M.H., and Carapetis J.R. Group A streptococcal infections in children. J Paediatr Child Health 43 4 (2007) 203-213
4. Rodriguez-Iturbe B., and Musser J.M. The current state of poststreptococcal glomerulonephritis. J Am Soc Nephrol 19 10 (2008) 1855-1864
5. Rodriguez-Iturbe B., Rubio L., and Garcia R. Attack rate of poststreptococcal nephritis in families. A prospective study. Lancet 1 8217 (1981) 401-403
6. Sagel I., Treser G., Ty A., et al. Occurrence and nature of glomerular lesions after group A streptococci infections in children. Ann Intern Med 79 4 (1973) 492-499
7. Stetson C.A., Rammelkamp Jr. C.H., Krause R.M., et al. Epidemic acute nephritis: studies on etiology, natural history and prevention. Medicine (Baltimore) 34 4 (1955) 431-450
8. Tejani A., and Ingulli E. Poststreptococcal glomerulonephritis. Current clinical and pathologic concepts. Nephron 55 1 (1990) 1-5
9. Kanjanabuch T., Kittikowit W., and Eiam-Ong S. An update on acute postinfectious glomerulonephritis worldwide. Nat Rev Nephrol 5 5 (2009) 259-269
10. Yoshizawa N. Acute glomerulonephritis. Intern Med 39 9 (2000) 687-694
11. Ilyas M., and Tolaymat A. Changing epidemiology of acute post-streptococcal glomerulonephritis in Northeast Florida: a comparative study. Pediatr Nephrol 23 7 (2008) 1101-1106
12. Yap H.K., Chia K.S., Murugasu B., et al. Acute glomerulonephritis-changing patterns in Singapore children. Pediatr Nephrol 4 5 (1990) 482-484
13. Markowitz M. Changing epidemiology of group A streptococcal infections. Pediatr Infect Dis J 13 6 (1994) 557-560
14. White A.V., Hoy W.E., and McCredie D.A. Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life. Med J Aust 174 10 (2001) 492-496
15. Streeton C.L., Hanna J.N., Messer R.D., et al. An epidemic of acute post-streptococcal glomerulonephritis among aboriginal children. J Paediatr Child Health 31 3 (1995) 245-248
16. Marshal C., and Taylor C. Northern Territory Disease Control Bulletin 15 3 (2008) 1-4
17. Wong W., Morris M.C., and Zwi J. Outcome of severe acute post-streptococcal glomerulonephritis in New Zealand children. Pediatr Nephrol 24 5 (2009) 1021-1026
18. Pan C.G. Evaluation of gross hematuria. Pediatr Clin North Am 53 3 (2006) 401-412 vi
19. Pan C.G. Glomerulonephritis in childhood. Curr Opin Pediatr 9 2 (1997) 154-159
20. El-Husseini A.A., Sheashaa H.A., Sabry A.A., et al. Acute postinfectious crescentic glomerulonephritis: clinicopathologic presentation and risk factors. Int Urol Nephrol 37 3 (2005) 603-609
21. Tasic V., and Polenakovic M. Occurrence of subclinical post-streptococcal glomerulonephritis in family contacts. J Paediatr Child Health 39 3 (2003) 177-179
22. Sorger K., Gessler U., Hubner F.K., et al. Subtypes of acute postinfectious glomerulonephritis. Synopsis of clinical and pathological features. Clin Nephrol 17 3 (1982) 114-128
23. Seegal D., and Earle D.P. A consideration of certain biological differences between glomerulonephritis and rheumatic fever. Am J Med Sci 201 (1941) 528-539
24. Rodriguez-Iturbe B., and Batsford S. Pathogenesis of poststreptococcal glomerulonephritis a century after Clemens von Pirquet. Kidney Int 71 11 (2007) 1094-1104
25. Batsford S.R., Mezzano S., Mihatsch M., et al. Is the nephritogenic antigen in post-streptococcal glomerulonephritis pyrogenic exotoxin B (SPE B) or GAPDH?. Kidney Int 68 3 (2005) 1120-1129
26. Read S.E., Reid H., Poon-King T., et al. HLA and predisposition to the nonsuppurative sequelae of group A streptococcal infections. Transplant Proc 9 1 (1977) 543-546
27. Layrisse Z., Rodriguez-Iturbe B., Garcia-Ramirez R., et al. Family studies of the HLA system in acute post-streptococcal glomerulonephritis. Hum Immunol 7 3 (1983) 177-185
28. Bakr A., Mahmoud L.A., Al-Chenawi F., et al. HLA-DRB1* alleles in Egyptian children with post-streptococcal acute glomerulonephritis. Pediatr Nephrol 22 3 (2007) 376-379
29. Dursun H., Noyan A., Matyar S., et al. Endothelial nitric oxide synthase gene intron 4 a/b VNTR polymorphism in children with APSGN. Pediatr Nephrol 21 11 (2006) 1661-1665
30. Robson W.L., and Leung A.K. Post-streptococcal glomerulonephritis with minimal abnormalities in the urinary sediment. J Singapore Paediatr Soc 34 3-4 (1992) 232-234
31. Kallen A.J., and Patel P.R. In search of a rational approach to chronic kidney disease detection and management. Kidney Int 72 1 (2007) 3-5
32. Morsi M.R., Madina E.H., Anglo A.A., et al. Evaluation of captopril versus reserpine and frusemide in treating hypertensive children with acute post-streptococcal glomerulonephritis. Acta Paediatr 81 2 (1992) 145-149
33. Parra G., Rodriguez-Iturbe B., Colina-Chourio J., et al. Short-term treatment with captopril in hypertension due to acute glomerulonephritis. Clin Nephrol 29 2 (1988) 58-62
34. Raff A., Hebert T., Pullman J., et al. Crescentic post-streptococcal glomerulonephritis with nephrotic syndrome in the adult: is aggressive therapy warranted?. Clin Nephrol 63 5 (2005) 375-380
35. Suyama K., Kawasaki Y., and Suzuki H. Girl with garland-pattern poststreptococcal acute glomerulonephritis presenting with renal failure and nephrotic syndrome. Pediatr Int 49 1 (2007) 115-117
36. Garin E.H., and Araya C.E. Treatment of systemic hypertension in children and adolescents. Curr Opin Pediatr (2009) [Epub ahead of print]
37. Smith R.J., Alexander J., Barlow P.N., et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 18 9 (2007) 2447-2456
38. Johnston F., Carapetis J., Patel M.S., et al. Evaluating the use of penicillin to control outbreaks of acute poststreptococcal glomerulonephritis. Pediatr Infect Dis J 18 4 (1999) 327-332
39. Bergholm A.M., and Holm S.E. Effect of early penicillin treatment on the development of experimental poststreptococcal glomerulonephritis. Acta Pathol Microbiol Immunol Scand C 91 4 (1983) 271-281
40. Buzio C., Allegri L., Mutti A., et al. Significance of albuminuria in the follow-up of acute poststreptococcal glomerulonephritis. Clin Nephrol 41 5 (1994) 259-264
41. Cleper R., Davidovitz M., Halevi R., et al. Renal functional reserve after acute poststreptococcal glomerulonephritis. Pediatr Nephrol 11 4 (1997) 473-476
42. Blyth C.C., Robertson P.W., and Rosenberg A.R. Post-streptococcal glomerulonephritis in Sydney: a 16-year retrospective review. J Paediatr Child Health 43 6 (2007) 446-450
43. Sesso R., and Pinto S.W. Five-year follow-up of patients with epidemic glomerulonephritis due to Streptococcus zooepidemicus. Nephrol Dial Transplant 20 9 (2005) 1808-1812
44. Sesso R., Wyton S., and Pinto L. Epidemic glomerulonephritis due to Streptococcus zooepidemicus in Nova Serrana, Brazil. Kidney Int Suppl 97 (2005) S132-S136
45. Yamagata K., Iseki K., Nitta K., et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 12 1 (2008) 1-8
46. Hoy W., Kelly A., Jacups S., et al. Stemming the tide: reducing cardiovascular disease and renal failure in Australian Aborigines. Aust N Z J Med 29 3 (1999) 480-483
47. Van Buynder P.G., Gaggin J.A., Martin D., et al. Streptococcal infection and renal disease markers in Australian aboriginal children. Med J Aust 156 8 (1992) 537-540
48. Georgousakis M.M., McMillan D.J., Batzloff M.R., et al. Moving forward: a mucosal vaccine against group A streptococcus. Expert Rev Vaccines 8 6 (2009) 747-760
49. Centers for Disease Control and Prevention (CDC). End-stage renal disease attributed to diabetes among American Indians/Alaska Natives with diabetes-United States, 1990-1996. MMWR Morb Mortal Wkly Rep 49 42 (2000) 959-962
50. Orr N.I., McDonald S.P., McTaggart S., et al. Frequency, etiology and treatment of childhood end-stage kidney disease in Australia and New Zealand. Pediatr Nephrol 24 9 (2009) 1719-1726
51. McDonald S.P., Russ G.R., Kerr P.G., et al. ESRD in Australia and New Zealand at the end of the millennium: a report from the ANZDATA registry. Am J Kidney Dis 40 6 (2002) 1122-1131
52. Ansell D., and Tomson C.R. Evolving trends in clinical presentation of and renal replacement therapy for chronic kidney disease. Nephron Clin Pract 111 4 (2009) c265-c267
53. Ramsay C.R., Campbell M.K., Cantarovich D., et al. Evaluation of clinical guidelines for the management of end-stage renal disease in europe: the EU BIOMED 1 study. Nephrol Dial Transplant 15 9 (2000) 1394-1398
54. Korevaar J.C., Jansen M.A., Dekker F.W., et al. Evaluation of DOQI guidelines: early start of dialysis treatment is not associated with better health-related quality of life. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 39 1 (2002) 108-115
55. Glassock R.J. The rising tide of end-stage renal disease: what can be done?. Clin Exp Nephrol 8 4 (2004) 291-296
56. de Zeeuw D., Hillege H.L., and de Jong P.E. The kidney, a cardiovascular risk marker, and a new target for therapy. Kidney Int Suppl 98 (2005) S25-S29
57. Brantsma A.H., Atthobari J., Bakker S.J., et al. What predicts progression and regression of urinary albumin excretion in the nondiabetic population?. J Am Soc Nephrol 18 2 (2007) 637-645
58. Kestenbaum B., Rudser K.D., de Boer I.H., et al. Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis. Ann Intern Med 148 7 (2008) 501-508
59. Zhang Q.L., and Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 8 (2008) 117
60. Chadban S.J., Briganti E.M., Kerr P.G., et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol 14 7 Suppl 2 (2003) S131-S138
61. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 298 17 (2007) 2038-2047
62. Stewart J.H., McCredie M.R., and McDonald S.P. Incidence of end-stage renal disease in overseas-born, compared with Australian-born, non-indigenous Australians. Nephrology (Carlton) 9 4 (2004) 247-252
63. Tonelli M., Hemmelgarn B., Manns B., et al. Death and renal transplantation among Aboriginal people undergoing dialysis. CMAJ 171 6 (2004) 577-582
64. Gilbertson D., Burrows N.R., Wang J., et al. Centers for Disease Control and Prevention (CDC). Racial differences in trends of end-stage renal disease, by primary diagnosis-United States, 1994-2004. MMWR Morb Mortal Wkly Rep 56 11 (2007) 253-256
65. Snyder J.J., Foley R.N., and Collins A.J. Prevalence of CKD in the United States: a sensitivity analysis using the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 53 2 (2009) 218-228
66. Keith D.S., Nichols G.A., Gullion C.M., et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164 6 (2004) 659-663
67. Scavini M., Stidley C.A., Paine S.S., et al. The burden of chronic kidney disease among the Zuni Indians: the Zuni Kidney Project. Clin J Am Soc Nephrol 2 3 (2007) 509-516
68. White S.L., Chadban S.J., Jan S., et al. How can we achieve global equity in provision of renal replacement therapy?. Bull World Health Organ 86 3 (2008) 229-237
69. Dirks J.H., de Zeeuw D., Agarwal S.K., et al. Prevention of chronic kidney and vascular disease: toward global health equity-the Bellagio 2004 Declaration. Kidney Int Suppl 98 (2005) S1-S6
70. Hoy W.E., Kondalsamy-Chennakesavan S., McDonald S., et al. Renal disease, the metabolic syndrome, and cardiovascular disease. Ethn Dis 16 2 Suppl 2 (2006) S246-51
71. Neild G.H. What do we know about chronic renal failure in young adults? I. Primary renal disease. Pediatr Nephrol 24 10 (2009) 1921-1928
72. Ardissino G., Dacco V., Testa S., et al. Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics 111 4 Pt 1 (2003) e382-e387
73. Lewis M.A. Demography of renal disease in childhood. Semin Fetal Neonatal Med 13 3 (2008) 118-124
74. Seikaly M., Ho P.L., Emmett L., et al. The 12th annual report of the North American Pediatric Renal Transplant Cooperative Study: renal transplantation from 1987 through 1998. Pediatr Transplant 5 3 (2001) 215-231
75. Barsoum R.S. Chronic kidney disease in the developing world. N Engl J Med 354 10 (2006) 997-999
76. Zhang R., Liao J., Morse S., et al. Kidney disease and the metabolic syndrome. Am J Med Sci 330 6 (2005) 319-325
77. Castro A.F., and Coresh J. CKD surveillance using laboratory data from the population-based National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 53 3 Suppl 3 (2009) S46-S55
78. Mackenzie H.S., Lawler E.V., and Brenner B.M. Congenital oligonephropathy: the fetal flaw in essential hypertension?. Kidney Int Suppl 55 (1996) S30-S34
79. Mackenzie H.S., and Brenner B.M. Fewer nephrons at birth: a missing link in the etiology of essential hypertension?. Am J Kidney Dis 26 1 (1995) 91-98
80. Shah V.O., Scavini M., Stidley C.A., et al. Epidemic of diabetic and nondiabetic renal disease among the Zuni Indians: the Zuni Kidney Project. J Am Soc Nephrol 14 5 (2003) 1320-1329
81. Young T.K., Reading J., Elias B., et al. Type 2 diabetes mellitus in Canada's first nations: status of an epidemic in progress. CMAJ 163 5 (2000) 561-566
82. Nelson R.G. Kidney disease in childhood-onset diabetes. Am J Kidney Dis 52 3 (2008) 407-411
83. Hovind P., Tarnow L., and Parving H.H. Remission and regression of diabetic nephropathy. Curr Hypertens Rep 6 5 (2004) 377-382
84. Sego S. Pathophysiology of diabetic nephropathy. Nephrol Nurs J 34 6 (2007) 631-633
85. Pavkov M.E., Bennett P.H., Knowler W.C., et al. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 296 4 (2006) 421-426
86. Sellers E.A., Blydt-Hansen T.D., Dean H.J., et al. Macroalbuminuria and renal pathology in First Nation youth with type 2 diabetes. Diabetes Care 32 5 (2009) 786-790
87. Praga M., and Morales E. Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens 15 5 (2006) 481-486
88. Hall J.E., Henegar J.R., Dwyer T.M., et al. Is obesity a major cause of chronic kidney disease?. Adv Ren Replace Ther 11 1 (2004) 41-54
89. Knowler W.C., Pettitt D.J., Saad M.F., et al. Obesity in the Pima Indians: its magnitude and relationship with diabetes. Am J Clin Nutr 53 Suppl 6 (1991) 1543S-1551S
90. Chen H.M., Li S.J., Chen H.P., et al. Obesity-related glomerulopathy in China: a case series of 90 patients. Am J Kidney Dis 52 1 (2008) 58-65
91. Fowler S.M., Kon V., Ma L., et al. Obesity-related focal and segmental glomerulosclerosis: normalization of proteinuria in an adolescent after bariatric surgery. Pediatr Nephrol 24 4 (2009) 851-855
92. Wu Y., Liu Z., Xiang Z., et al. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology 147 1 (2006) 44-50
93. Kambham N., Markowitz G.S., Valeri A.M., et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59 4 (2001) 1498-1509
94. Remuzzi G., Ruggenenti P., and Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 136 8 (2002) 604-615
95. Kojima T., Sasai-Takedatsu M., Hirata Y., et al. Characterization of renal tubular damage in preterm infants with renal failure. Acta Paediatr Jpn 36 4 (1994) 392-395
96. Hodgin J.B., Rasoulpour M., Markowitz G.S., et al. Very low birth weight is a risk factor for secondary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 4 1 (2009) 71-76
97. Yeung M.Y. Oligonephropathy, developmental programming and nutritional management of low-gestation newborns. Acta Paediatr 95 3 (2006) 263-267
98. Al Salmi I., Hoy W.E., Kondalsamy-Chennakes S., et al. Birth weight and stages of CKD: a case-control study in an Australian population. Am J Kidney Dis 52 6 (2008) 1070-1078
99. Lindstrom J., Eriksson J.G., Valle T.T., et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. J Am Soc Nephrol 14 7 Suppl 2 (2003) S108-S113
100. Lindstrom J., Peltonen M., and Tuomilehto J. Lifestyle strategies for weight control: experience from the Finnish Diabetes Prevention Study. Proc Nutr Soc 64 1 (2005) 81-88
101. Type 1 diabetes: benefits of intensive insulin therapy. Patients should control blood glucose strictly. Prescrire Int 11 58 (2002) 61
102. Genuth S. The UKPDS and its global impact. Diabet Med 25 Suppl 2 (2008) 57-62
103. Sandhu S., Wiebe N., Fried L.F., et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17 7 (2006) 2006-2016
104. Fried L.F. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int 74 5 (2008) 571-576
105. Hillege H.L., Janssen W.M., Bak A.A., et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 249 6 (2001) 519-526
106. Hoy W.E., Kondalsamy-Chennakesavan S., Scheppingen J., et al. A chronic disease outreach program for Aboriginal communities. Kidney Int Suppl 98 (2005) S76-S82
107. Mann J.F., Gerstein H.C., Pogue J., et al. Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. Am J Cardiovasc Drugs 2 3 (2002) 157-162
108. Groothoff J.W. Long-term outcomes of children with end-stage renal disease. Pediatr Nephrol 20 7 (2005) 849-853
109. Groothoff J., Gruppen M., de Groot E., et al. Cardiovascular disease as a late complication of end-stage renal disease in children. Perit Dial Int 25 Suppl 3 (2005) S123-S126
110. Ishimura E., Okuno S., Taniwaki H., et al. Different risk factors for vascular calcification in end-stage renal disease between diabetics and nondiabetics: the respective importance of glycemic and phosphate control. Kidney Blood Press Res 31 1 (2008) 10-15
111. Lin C.Y., Sheng C.C., Lin C.C., et al. Mass urinary screening and follow-up for school children in Taiwan Province. Acta Paediatr Taiwan 42 3 (2001) 134-140
112. Iseki K. Chronic kidney disease in Japan. Intern Med 47 8 (2008) 681-689
113. Hillege H.L., Fidler V., Diercks G.F., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106 14 (2002) 1777-1782
114. Magnason R.L., Indridason O.S., Sigvaldason H., et al. Prevalence and progression of CRF in Iceland: a population-based study. Am J Kidney Dis 40 5 (2002) 955-963
115. Ramirez S.P. A comprehensive public health approach to address the burden of renal disease in singapore. J Am Soc Nephrol 14 7 Suppl 2 (2003) S122-S126
116. Mani M.K. Prevention of chronic renal failure at the community level. Kidney Int Suppl 83 (2003) S86-S89
117. Haysom L., Williams R., Hodson E., et al. Risk of CKD in Australian indigenous and nonindigenous children: a population-based cohort study. Am J Kidney Dis 53 2 (2009) 229-237
118. Stidley C.A., Shah V.O., Narva A.S., et al. A population-based, cross-sectional survey of the Zuni Pueblo: a collaborative approach to an epidemic of kidney disease. Am J Kidney Dis 39 2 (2002) 358-368
119. Stidley C.A., Shah V.O., Scavini M., et al. The Zuni kidney project: a collaborative approach to an epidemic of kidney disease. J Am Soc Nephrol 14 7 Suppl 2 (2003) S139-S143
120. Archibald G., Bartlett W., Brown A., et al. UK Consensus Conference on early chronic kidney disease-6 and 7 February 2007. Nephrol Dial Transplant 22 9 (2007) 2455-2457
121. Powe N.R., Plantinga L., and Saran R. Public health surveillance of CKD: principles, steps, and challenges. Am J Kidney Dis 53 3 Suppl 3 (2009) S37-S45
122. Yap H.K., Quek C.M., Shen Q., et al. Role of urinary screening programmes in children in the prevention of chronic kidney disease. Ann Acad Med Singap 34 1 (2005) 3-7
123. Scavini M., Shah V.O., Stidley C.A., et al. Kidney disease among the Zuni Indians: the Zuni Kidney Project. Kidney Int Suppl 97 (2005) S126-S131
124. Vassalotti J.A., Li S., Chen S.C., et al. Screening populations at increased risk of CKD: the Kidney Early Evaluation Program (KEEP) and the public health problem. Am J Kidney Dis 53 3 Suppl 3 (2009) S107-S114
125. Fox C.S., Larson M.G., Leip E.P., et al. Predictors of new-onset kidney disease in a community-based population. JAMA 291 7 (2004) 844-850
126. Iseki K. Screening for renal disease-what can be learned from the Okinawa experience. Nephrol Dial Transplant 21 4 (2006) 839-843
127. Winberg J. Does low birthweight facilitate postinfectious focal renal scarring?. Acta Paediatr 90 8 (2001) 835-836
128. Vikse B.E., Irgens L.M., Leivestad T., et al. Low birth weight increases risk for end-stage renal disease. J Am Soc Nephrol 19 1 (2008) 151-157
129. Wani M., Kalra V., and Agarwal S.K. Low birth weight and its implication in renal disease. J Assoc Physicians India 52 (2004) 649-652
130. Bolignano D., Donato V., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 52 3 (2008) 595-605
131. Lindstrom J., Ilanne-Parikka P., Peltonen M., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368 9548 (2006) 1673-1679
132. Molitch M.E., Fujimoto W., Hamman R.F., et al. The diabetes prevention program and its global implications. J Am Soc Nephrol 14 7 Suppl 2 (2003) S103-S107
133. Perneger T.V., Whelton P.K., Puddey I.B., et al. Risk of end-stage renal disease associated with alcohol consumption. Am J Epidemiol 150 12 (1999) 1275-1281
134. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 47 6 (1995) 1703-1720
135. Home P.D. Impact of the UKPDS-an overview. Diabet Med 25 Suppl 2 (2008) 2-8
136. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 9131 (1998) 837-853
137. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317 7160 (1998) 703-713
138. Bomback A.S., Kshirsagar A.V., Amamoo M.A., et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 51 2 (2008) 199-211
139. Ruggenenti P., Perna A., and Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril efficacy in nephropathy. J Am Soc Nephrol 12 12 (2001) 2832-2837
140. Tonelli M., Bohm C., Pandeya S., et al. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 37 3 (2001) 484-489
141. Wald N.J., and Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326 7404 (2003) 1419